Relafen (nabumetone)
/ GSK
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
66
Go to page
1
2
3
December 12, 2025
From chronic gastritis to gastric cancer: Mendelian randomisation and multi-omics interrogation of leukaemia inhibitory factor receptor (LIFR), hepatocyte growth factor (HGF), serine protease inhibitor E1 (SERPINE1) and interleukin-10 receptor subunit beta (IL10RB).
(PubMed, Int J Biol Macromol)
- "Collectively, these data define a molecular continuum from chronic gastritis to GC and highlight LIFR, IL10RB, SERPINE1 and HGF as pivotal biological macromolecules and candidate therapeutic targets. The repurposing potential of anti-inflammatory agents, particularly rofecoxib and nabumetone, suggests a feasible strategy to intercept the gastritis-carcinoma sequence."
Journal • Gastric Cancer • Gastrointestinal Disorder • Hematological Malignancies • Leukemia • Oncology • Solid Tumor • IL10 • LIFR • SERPINE1
October 18, 2025
Kidney Safety of Nonsteroidal Anti-Inflammatory Drugs in Patients with Arthritis: A Network Meta-Analysis
(KIDNEY WEEK 2025)
- "NSAIDs evaluated were naproxen (n=17,185), ibuprofen (n=28,531), celecoxib (n=37,843), oral diclofenac (n=6,060), rofecoxib (n=804), nabumetone (n=15), valdecoxib (n=544), and amtolmetin guacil (n=30)...Conclusion Rofecoxib, naproxen, and diclofenac are associated with a higher incidence of renal AEs, edema, and HTN compared with placebo, respectively. Physicians should weigh renal safety when prescribing NSAIDs for arthritis."
Retrospective data • Immunology • Osteoarthritis • Rheumatoid Arthritis • Rheumatology
August 30, 2025
Safety of COX-2 Inhibitor NSAIDs in Inflammatory Bowel Disease: A Propensity-Matched Cohort Study Using Real-World Data
(ACG 2025)
- "Selective COX-2: celecoxib; preferential COX-2: meloxicam, nabumetone, etodolac. Across four matched cohorts (two in UC and two in CD), sample sizes ranged from 805 to 3,009 per group. In UC, the primary composite outcome occurred in 5.2%–5.8% of patients across comparisons, with no significant differences observed. In CD, the primary outcome ranged from 5.9%–7.0%, also without significant associations."
Clinical • Real-world • Real-world evidence • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis
August 11, 2025
Prescription Trends by Orthopedic Surgery Provider: Review of the Medicare Part D Prescribers - by Provider and Drug, 2013-2021.
(PubMed, Orthopedics)
- "In line with national guidelines, claims for NSAIDs are increasing and claims for opioid pain medications and AOMs are decreasing. Claims for outpatient antibiotics are increasing, which is of significant concern, given renewed focus on antibiotic stewardship."
Journal • Medicare • Reimbursement • Review • US reimbursement • Orthopedics • Pain
June 27, 2025
Host-Guest Interactions of Cucurbit[7]uril with Nabumetone and Naproxen: Spectroscopic, Calorimetric, and DFT Studies in Aqueous Solution.
(PubMed, Molecules)
- "The inclusion phenomena were further confirmed by NMR spectroscopy (1H, ROESY, and DOSY), suggesting the encapsulation of the naphthalene ring of both drugs inside the CB7 cavity. The results of the DFT calculations and the IGMH analysis were in accordance with the experimental ones, suggesting that van der Waals interactions play a major role in drug-CB7 complexation."
Journal
June 27, 2025
Novel aryl hydrocarbon receptor agonists as potential anti-inflammatory therapeutics: Identification and validation through drug repurposing.
(PubMed, Biochem Pharmacol)
- "While Febuxostat, Nitazoxanide, Rabeprazole, 2-(1'H-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester, 3-Indolepropionic acid, and Indirubin, were already known as AhR agonists, Nabumetone, Teriflunomide, Timapiprant/OC000459, and Caffeic acid phenylethyl ester have not yet been directly described in this context. Five candidates restored the epithelial barrier, as evidenced by increased transepithelial electrical resistance and induction of the tight junction proteins claudin-1/-2 and occludin, while exhibiting anti-inflammatory effects, i.e., decreased expression of toll-like receptor 4. Out of these, one compound was selected for future in vivo preclinical studies."
IO biomarker • Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • CLDN1 • CYP1A1 • IL1B • OCLN • TLR4
May 14, 2025
The Effects of Non-Steroidal Anti-Inflammatory Drugs Used for Orthodontic Pain Management on Tooth Movement: A Comprehensive Review of the Literature.
(PubMed, J Clin Med)
- "Evidence shows that NSAIDs such as aspirin, ketorolac, diclofenac, and nimesulide significantly reduce OTM. The results for ibuprofen, meloxicam, and celecoxib were inconsistent with both no influence or a reduction in OTM, depending on dosage, mode, and duration of administration. Conversely, tenoxicam, nabumetone, etoricoxib, and parecoxib appear to have no effect on OTM. Among these, etoricoxib appears particularly promising due to its favorable gastrointestinal profile, high COX-2 selectivity, and negligible influence on OTM in clinical doses. However, the limited number of human trials highlights the need for further research to develop evidence-based guidelines for pain management that preserve treatment efficiency in orthodontics."
Journal • Review • Pain
May 01, 2025
Graduation Research in Organic Chemistry: Transformation of Students' Attitude toward Research through Graduation Research
(PubMed, Yakugaku Zasshi)
- "For example, in research to determine the absolute configuration of metabolites of the antibiotic nabumetone, students managed their own schedules and became able to conduct research with a sense of conviction and responsibility. In addition, in research on the synthesis of thiophene derivatives, presenting multiple synthetic routes and allowing students to choose one enabled them to propose the direction of the experiment based on their own opinions. Therefore, it is necessary to devise and support research procedures tailored to individual students."
Journal
February 17, 2025
Mercapto-NSAIDs generate a non-steroidal anti-inflammatory drug (NSAID) and hydrogen sulfide.
(PubMed, Chem Sci)
- "We show that α-mercapto-nabumetone, a derivative of the clinical drug nabumetone, is a substrate for 3-mercaptopyruvate sulfurtransferase (3-MST), an enzyme involved in H2S biosynthesis...This offers new insights into 3-MST catalysis and how reaction outcomes can be modulated by the keto-enol equilibrium. Taken together, the atom economical transformation of a clinical NSAID with one strategically placed sulfhydryl group to generate H2S presents new opportunities to enhance the properties of NSAIDs through participation in endogenous H2S biosynthesis."
Journal • Inflammation • Pain
January 12, 2025
Radiolytic Elimination of Nabumetone from Aqueous Solution: Degradation Efficiency, and Degradants' Toxicity.
(PubMed, Molecules)
- "These results underline the importance of optimizing irradiation parameters for effective degradation and minimizing the formation of harmful by-products. Understanding all aspects of the AOP processes and the toxicological effects of the degradation products ensures effective mitigation of potential environmental and health risks of water treatment processes."
Journal
September 22, 2024
Synthesis, nonlinear optical activity, solvents effect, β-cyclodextrin effect, and cytotoxic activity on skin fibroblast and breast cancer cell lines of a new chalcone derivative of nabumetone.
(PubMed, Spectrochim Acta A Mol Biomol Spectrosc)
- "Cell biocompatibility was evaluated after culturing skin fibroblasts and breast cancer cells with INM using the MTT assay and fluorescence microscopy of the live/dead cell assay. It was observed that INM exhibited good NIH/3T3 cell adhesion and proliferation and the weak inhibiting ability of MDA-MB231."
Journal • Preclinical • Breast Cancer • Oncology • Solid Tumor
April 06, 2024
Clinical Evolution Of Adults Diagnosed of Hypersensitivity Reactions To NSAIDs
(EAACI 2024)
- "Our aim was to evaluate the clinical evolution of adults diagnosed of NIUA in our unit Method A prospective study was carried out evaluating patients (>18 y.o) diagnosed of NIUA, all of them diagnosed by a positive initial drug provocation test(iDPT) with acetyl-salicylic acid(ASA), between 2009-2019...Concerning the culprit NSAID, ibuprofen was involved in 49%, naproxen in 13,3%, dexketoprofen in 8,8%, ASA in 8,8%, dipyrone in 8,8%, paracetamol in 4,4% and diclofenac, indomethacin and nabumetone in 2,2% respectively...Rechallenge should be considered in patients with NIUA in order to assess the persistence or not of hypersensitivity to NSAIDs. More studies are in progress in order to investigate this observation."
Clinical • Allergy • Atopic Dermatitis • Dermatitis • Immunology
May 25, 2024
Clinical Evolution Of Adults Diagnosed of Hypersensitivity Reactions To NSAIDs
(EAACI 2024)
- "Our aim was to evaluate the clinical evolution of adults diagnosed of NIUA in our unit Method A prospective study was carried out evaluating patients (>18 y.o) diagnosed of NIUA, all of them diagnosed by a positive initial drug provocation test(iDPT) with acetyl-salicylic acid(ASA), between 2009-2019...Concerning the culprit NSAID, ibuprofen was involved in 49%, naproxen in 13,3%, dexketoprofen in 8,8%, ASA in 8,8%, dipyrone in 8,8%, paracetamol in 4,4% and diclofenac, indomethacin and nabumetone in 2,2% respectively...Rechallenge should be considered in patients with NIUA in order to assess the persistence or not of hypersensitivity to NSAIDs. More studies are in progress in order to investigate this observation."
Clinical • Allergy • Atopic Dermatitis • Dermatitis • Immunology
March 26, 2024
Degradation behaviors of Nabumetone and its metabolite during UV/monochloramine process: Experimental and theoretical study.
(PubMed, J Environ Sci (China))
- "The transformation products of both NMT and MNA exhibited higher mutagenicity than their parent compounds. This study provides a deep understanding of the mechanism of radical degradation of NMT and MNA in the treatment of UV/NH2Cl."
Journal
January 11, 2024
Dissecting CYP1A2 Activation by Arylalkanoic Acid Prodrugs toward the Development of Anti-Inflammatory Agents.
(PubMed, Int J Mol Sci)
- "Of note, all the examined compounds proved capable of interacting with the enzyme active site in a manner similar to Nabumetone, thus confirming that a productive metabolic transformation is feasible. On the basis of these findings, it is possible to argue that subtle differences in the way CYP1A2 accommodates the ligands depend on the fine details of their molecular structures. Overall, these data suggest that compounds simply formed by an aromatic moiety bearing an appropriate alkane-derived chain could lead to innovative anti-inflammatory agents."
Journal • CYP1A2
December 06, 2023
Nabumetone and flufenamic acid pose a serious risk to aquatic plants: A study with Chlamydomonas reinhardtii as a model organism.
(PubMed, Chemosphere)
- "No significant alteration in the ultrastructure of treated cells could be seen, except for changes in starch grain number and autophagic vacuoles that appeared in FFA-treated cells. To the best of our knowledge, this is the first work reporting the toxic effects of NBT and FFA on unicellular green algae."
Journal
October 15, 2023
Giant Bladder Stone in a Young Male: When Surgery Complements Medicine for Better Outcomes
(KIDNEY WEEK 2023)
- "Case Description A 68-year-old male with history of rheumatoid arthritis on adalimumab was re-admitted with altered mental status, poor oral intake and AKI after a recent hospitalization for lumbar osteomyelitis requiring long term intravenous (IV) cefepime...Hemodialysis was contemplated due to worsening renal function with creatinine at 8.4 mg/dl (reference range: 0.5 - 1 mg/dl), hyperkalemia and concern for uremic encephalopathy, but he responded to supportive care with IV fluids and IV piperacillin tazobactam. A thorough history revealed intake of nabumetone for several years at doses as high as 1.5 gm daily...AKI developed during hospitalization has high mortality. A thorough understanding of etiology, clinical course and having a low threshold for kidney biopsy aids in diagnosis of AKI with possibilities of better outcomes in the elderly population."
Surgery • Acute Kidney Injury • CNS Disorders • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Nephrology • Renal Disease • Rheumatoid Arthritis • Rheumatology
June 28, 2023
Application of TGA/c-DTA for Distinguishing between Two Forms of Naproxen in Pharmaceutical Preparations.
(PubMed, Pharmaceutics)
- "In addition, using nabumetone, a close structural analog of naproxen, the specificity of the TGA and c-DTA methods was assessed. Studies have shown that the thermal analyses used are effective and selective in distinguishing the form of naproxen in pharmaceutical preparations. This indicates the potential possibility of using TGA supported by c-DTA as an alternative method."
Journal • Inflammation • Pain
May 18, 2023
Knee Pain In A Recreational Runner
(ACSM 2023)
- "There was full range of motion bilaterally.DIFFERENTIAL DIAGNOSIS1.Patellar tendonitis 2.Meniscal injury3.Tibial stress fractures with loose bodyTEST AND RESULTSBilateral knee with flexion and patella radiographs: -Mild medial compartment osteoarthritis bilaterally -Osteochondral defect involving the right medial femoral condyle-Large loose fragment within the intercondylar notch on the right-Patellar enthesopathy bilaterallyBilateral knee MRI without contrast:-Stress fracture of the medial aspect of the proximal tibial metaphysis extending to the intercondylar eminence, left -Stress fracture at the medial aspect of the proximal tibial metaphysis, right-Large osteochondral defect of the medial femoral condyle with detached fragment, rightBone mineral density: -Hip: T-score -2.0; Z-score -1.3FINAL/ WORKING DIAGNOSISBilateral tibial stress fractures with right knee loose body from osteochondritis dissecans lesionTREATMENT AND OUTCOMES1.Pain control with ketorolac (in..."
Immunology • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Osteoarthritis • Osteoporosis • Pain • Rheumatology
February 02, 2023
Identification of HSD17B12 as an enzyme catalyzing drug reduction reactions through investigation of nabumetone metabolism.
(PubMed, Arch Biochem Biophys)
- "In conclusion, our study demonstrated that HSD17B12 is responsible for the formation of MNBO from nabumetone. Together with the evidence for pentoxifylline and S-warfarin reduction, this is the first study to report that HSD17B12, which is known to metabolize endogenous compounds, such as estrone and 3-ketoacyl-CoA, plays a role as a drug-metabolizing enzyme."
Journal
November 30, 2022
"@costplusdrugs @mcuban You are greatly appreciated! Victim of #HitAndRun in '74. #ChronicPainMeds hurt my stomach. @GSK had #Relafen trials. #Nonaddictive I participated. 👍🏾 You carry #Nabumetone 👍🏾 [generic] #Nonaddictive + other meds. Same meds/great savings!"
(@caviar_diva)
June 11, 2022
Identification of Gut Bacterial Enzymes for Keto-Reductive Metabolism of Xenobiotics.
(PubMed, ACS Chem Biol)
- "Through in vitro biochemical assays, we report the identification of enzymes encoded in the genome of Clostridium bolteae that can reduce the ketone groups of nabumetone, hydrocortisone, and tacrolimus. The selected enzymes display different levels of activities against additional chemicals such as two dietary compounds (i.e., raspberry ketone and zingerone), chemotherapeutic drug doxorubicin, and its aglycone metabolite doxorubicinone. Thus, our results expand the repertoire of enzymes that can reduce the ketone groups in small molecules and could serve as the basis for future personalized medicine approaches."
Journal • Gastrointestinal Disorder
January 28, 2022
Discovery and characterization of gut microbial enzymes involved in keto-reductive metabolism
(ACS-Sp 2022)
- "Here, we characterized an oxidoreductase from the human gut bacterium Clostridium bolteae capable of reducing the ketone groups residing in two drugs (i.e., nabumetone and hydrocortisone) and two ketone-bearing dietary chemicals (i.e., raspberry ketone and zingerone). In addition, we have also identified additional oxidoreductase homologues that have similar ketone-reducing activities from multiple human gut microbial species. Our results expand the gut bacterial enzymatic inventory for the ketone-reduction of pharmaceuticals and dietary chemicals, but it also serves as the basis for elucidating bacteria-chemical interactions and illuminating strategies for future personalized medicines and dietary plans."
January 26, 2022
A universal methodology for reliable predicting the non-steroidal anti-inflammatory drug solubility in supercritical carbon dioxide.
(PubMed, Sci Rep)
- "The considered NSAIDs are Fenoprofen, Flurbiprofen, Ibuprofen, Ketoprofen, Loxoprofen, Nabumetone, Naproxen, Nimesulide, Phenylbutazone, Piroxicam, Salicylamide, and Tolmetin. Experimental measurements, model predictions, and relevancy analyses justified that the drug solubility in SCCO increases by increasing temperature and pressure. The results show that Ibuprofen and Naproxen are the most soluble and insoluble drugs in SCCO, respectively."
Journal
December 27, 2021
Precision Medicine in Patients with Differential Diabetic Phenotypes: Novel Opportunities from Network Medicine.
(PubMed, Curr Diabetes Rev)
- "The interactome [or protein-protein interactions (PPIs)] is a useful tool to identify subtle molecular differences between precise diabetic phenotypes and predict putative novel drugs. Despite being previously unappreciated as T2DM determinants, the growth factor receptor-bound protein 14 (GRB14), calmodulin 2 (CALM2), and protein kinase C-alpha (PRKCA) might have a relevant role in disease pathogenesis. Besides, in silico platforms have suggested that diflunisal, nabumetone, niflumic acid, and valdecoxib may be suitable for the treatment of T1DM; phenoxybenzamine and idazoxan for the treatment of T2DM by improving insulin secretion; and hydroxychloroquine reduce the risk of coronary heart disease (CHD) by counteracting inflammation. Network medicine has the potential to improve precision medicine in diabetes care and enhance personalized therapy. However, only randomized clinical trials will confirm the clinical utility of network-oriented biomarkers and drugs in the..."
Clinical • Journal • Cardiovascular • Coronary Artery Disease • Diabetes • Gestational Diabetes • Heart Failure • Immunology • Inflammation • Metabolic Disorders • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus • CALM2 • PRKCA
1 to 25
Of
66
Go to page
1
2
3